XML 16 R7.htm IDEA: XBRL DOCUMENT

Group information	6 Months Ended
Group information	Jun. 30, 2022
Text Block [Abstract]
Group information	1. Group information Immatics N.V, together with its German subsidiary Immatics Biotechnologies GmbH and its U.S. subsidiary, Immatics US Inc., (“Immatics” or “the Group”) is a biotechnology group that is primarily engaged in the research and development of T cell redirecting immunotherapies for the treatment of cancer. Immatics N.V., a Dutch public limited liability company, was converted on July 1, 2020 from Immatics B.V., a Dutch company with limited liability. Immatics Biotechnologies GmbH and Immatics US Inc. became subsidiaries of Immatics N.V. as part of the ARYA Merger on July 1, 2020. Immatics N.V is registered with the commercial register at the Netherlands Chamber of Commerce under RSIN 861058926 with a corporate seat in Amsterdam and is located at Paul-Ehrlich Str. 15 in 72076 Tübingen, Germany. These interim condensed consolidated financial statements of the Group for the three and six months ended June 30, 2022, were authorized for issue by the Audit Committee of Immatics N.V. on August 9, 2022.